Cargando…
PB2230: EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT
Autores principales: | Karimi, M., Zarei, T., Haghpanah, S., Azarkeivan, A., Naderi, M., Matin, S., Bazrafshan, A., Zahedi, Z., Shirkavand, A., Pishdad, P., De Sanctis, V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429259/ http://dx.doi.org/10.1097/01.HS9.0000851748.27564.18 |
Ejemplares similares
-
Efficacy and Safety of Sinopharm Vaccine for SARS-CoV-2 and breakthrough infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report
por: Karimi, Mehran, et al.
Publicado: (2022) -
Prevalence and Severity of Coronavirus Disease 2019 (COVID-19) in Transfusion Dependent and Non-Transfusion Dependent β -Thalassemia Patients and effects of Associated Comorbidities: An Iranian Nationwide study
por: Karimi, Mehran, et al.
Publicado: (2020) -
Sinopharm Vaccine, SARS-CoV-2 Breakthrough Infections and Hemoglobinopathies
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022) -
PB2230: THE ORIGIN IN PRIMARY AND SECONDARY MYELOFIBROSIS: IS THE KEY THE PROGENITOR OR THE MOLECULAR SIGNATURE?
por: Cuadrado, Isabel Montero
Publicado: (2023) -
Coronavirus Disease 2019 (COVID-19) Severity in Patients with Thalassemias: A Nationwide Iranian Experience
por: Karimi, Mehran, et al.
Publicado: (2021)